ATE120451T1 - Peptidylderivate. - Google Patents

Peptidylderivate.

Info

Publication number
ATE120451T1
ATE120451T1 AT91311254T AT91311254T ATE120451T1 AT E120451 T1 ATE120451 T1 AT E120451T1 AT 91311254 T AT91311254 T AT 91311254T AT 91311254 T AT91311254 T AT 91311254T AT E120451 T1 ATE120451 T1 AT E120451T1
Authority
AT
Austria
Prior art keywords
group
alkyl
amino
alkenyl
hydrogen atom
Prior art date
Application number
AT91311254T
Other languages
English (en)
Inventor
John Robert Porter
Thomas Andrew Millican
John Richard Morphy
Nigel Robert Arnold Beeley
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909026251A external-priority patent/GB9026251D0/en
Priority claimed from GB919110338A external-priority patent/GB9110338D0/en
Priority claimed from GB919110339A external-priority patent/GB9110339D0/en
Priority claimed from GB919112888A external-priority patent/GB9112888D0/en
Priority claimed from GB919112901A external-priority patent/GB9112901D0/en
Priority claimed from GB919115038A external-priority patent/GB9115038D0/en
Priority claimed from GB919115039A external-priority patent/GB9115039D0/en
Priority claimed from GB919115916A external-priority patent/GB9115916D0/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE120451T1 publication Critical patent/ATE120451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
AT91311254T 1990-12-03 1991-12-03 Peptidylderivate. ATE120451T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB909026251A GB9026251D0 (en) 1990-12-03 1990-12-03 Netalloproteinase inhibitors
GB919110338A GB9110338D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919110339A GB9110339D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919112888A GB9112888D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919112901A GB9112901D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919115038A GB9115038D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115039A GB9115039D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115916A GB9115916D0 (en) 1991-07-23 1991-07-23 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE120451T1 true ATE120451T1 (de) 1995-04-15

Family

ID=27571285

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91311252T ATE120182T1 (de) 1990-12-03 1991-12-03 Peptidylderivate.
AT91311254T ATE120451T1 (de) 1990-12-03 1991-12-03 Peptidylderivate.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT91311252T ATE120182T1 (de) 1990-12-03 1991-12-03 Peptidylderivate.

Country Status (16)

Country Link
US (1) US5300501A (de)
EP (2) EP0489577B1 (de)
JP (2) JPH05503720A (de)
KR (2) KR927003521A (de)
AT (2) ATE120182T1 (de)
AU (2) AU652793B2 (de)
CA (2) CA2073510A1 (de)
DE (2) DE69108529T2 (de)
DK (1) DK0489579T3 (de)
ES (1) ES2069833T3 (de)
FI (2) FI923494A7 (de)
GB (2) GB2255339B (de)
GR (1) GR3015567T3 (de)
HU (3) HU9202497D0 (de)
NO (2) NO922967L (de)
WO (2) WO1992009564A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
EP0634998B1 (de) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
JPH08503475A (ja) * 1992-11-25 1996-04-16 メルク エンド カンパニー インコーポレーテッド 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08508027A (ja) * 1993-03-16 1996-08-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク加水分解酵素阻害剤である天然アミノ酸誘導体
JPH08511509A (ja) * 1993-04-07 1996-12-03 グリコメド・インコーポレイテッド 合成マトリックスメタロプロテアーゼ阻害剤およびその用途
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
JPH08500124A (ja) * 1993-04-27 1996-01-09 セルテック セラピューティックス リミテッド メタロプロテイナーゼインヒビターとしてのペプチジル誘導体
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
WO1995004033A1 (en) * 1993-08-02 1995-02-09 Celltech Limited Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
PT822186E (pt) * 1994-01-20 2000-08-31 British Biotech Pharm L-tert-leucina-2-piridilamida
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
ATE181055T1 (de) * 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
JPH10501806A (ja) * 1994-06-22 1998-02-17 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5857961A (en) * 1995-06-07 1999-01-12 Clarus Medical Systems, Inc. Surgical instrument for use with a viewing system
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
CZ292617B6 (cs) * 1995-11-23 2003-11-12 British Biotech Pharmaceuticals Limited Inhibitory metaloproteinázy a farmaceutický prostředek
ES2233275T3 (es) * 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
PL191366B1 (pl) 1996-09-10 2006-05-31 Vernalis Oxford Ltd Zastosowanie pochodnych kwasu hydroksamowego, pochodne kwasu hydroksamowego oraz kompozycje farmaceutyczne je zawierające
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JPH10130217A (ja) * 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0887077A1 (de) * 1997-06-27 1998-12-30 Roche Diagnostics GmbH Verwendung von Azulenderivaten als Metalloproteaseinhibitoren
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
CN1353689A (zh) * 1999-05-17 2002-06-12 第一精密化学株式会社 新的异羟肟酸衍生物
JP2001031637A (ja) * 1999-05-17 2001-02-06 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
EP1406893B1 (de) 2001-06-15 2007-04-18 Vicuron Pharmaceuticals, Inc. Bicyclische pyrrolidinverbindungen
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
US7605132B2 (en) * 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
WO2005090387A2 (en) * 2004-03-23 2005-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone h2a peptide derivatives and analogs and methods of use thereof
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US20040192658A1 (en) * 2002-12-27 2004-09-30 Angiotech International Ag Compositions and methods of using collajolie
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
WO2010118435A2 (en) 2009-04-10 2010-10-14 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
DE102014206916A1 (de) 2014-04-10 2015-10-15 Wacker Chemie Ag Verfahren zur Ruthenium-katalysierten Umvinylierung von Carbonsäuren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5196412A (en) * 1991-03-06 1993-03-23 Johnson Matthey, Inc. Gallium compounds

Also Published As

Publication number Publication date
KR927003520A (ko) 1992-12-18
AU652596B2 (en) 1994-09-01
GB9211715D0 (en) 1992-08-26
ES2069833T3 (es) 1995-05-16
KR927003521A (ko) 1992-12-18
FI923494L (fi) 1992-08-03
DE69108363T2 (de) 1995-08-31
AU652793B2 (en) 1994-09-08
HU9202498D0 (en) 1992-10-28
CA2073513A1 (en) 1992-06-04
GB9211714D0 (en) 1992-08-26
FI923495A0 (fi) 1992-08-03
NO922968D0 (no) 1992-07-28
GR3015567T3 (en) 1995-06-30
JPH05503720A (ja) 1993-06-17
HUT62263A (en) 1993-04-28
EP0489577B1 (de) 1995-03-22
FI923495A7 (fi) 1992-08-03
NO922968L (no) 1992-09-24
FI923494A0 (fi) 1992-08-03
DE69108363D1 (de) 1995-04-27
WO1992009565A1 (en) 1992-06-11
NO922967D0 (no) 1992-07-28
DE69108529T2 (de) 1995-11-30
WO1992009564A1 (en) 1992-06-11
GB2255340A (en) 1992-11-04
JPH05503719A (ja) 1993-06-17
EP0489579A1 (de) 1992-06-10
HU9202497D0 (en) 1992-10-28
ATE120182T1 (de) 1995-04-15
AU9023391A (en) 1992-06-25
AU9017391A (en) 1992-06-25
CA2073510A1 (en) 1992-06-04
HUT61973A (en) 1993-03-29
NO922967L (no) 1992-09-24
GB2255340B (en) 1994-09-28
EP0489577A1 (de) 1992-06-10
US5300501A (en) 1994-04-05
GB2255339B (en) 1994-10-05
EP0489579B1 (de) 1995-03-29
DE69108529D1 (de) 1995-05-04
DK0489579T3 (da) 1995-06-12
GB2255339A (en) 1992-11-04
FI923494A7 (fi) 1992-08-03

Similar Documents

Publication Publication Date Title
ATE120451T1 (de) Peptidylderivate.
AU645867B2 (en) 2-arylthiazole derivative and pharmaceutical composition containing the same
ATE71372T1 (de) Benzothiazol-derivat und es als aktiven bestandteil enthaltendes antirheumatisches mittel.
NO304111B1 (no) Heteroeddiksyrederivater, farmas°ytiske midler inneholdende dem samt deres anvendelse for fremstilling av farmas°ytiske preparater
AU1287183A (en) 2-azaspiro(4 )-3-carboxylic acid derivatives
MY131193A (en) 7-(2-aminoethyl)-benzothiazolones
DE3851279D1 (de) Organische Salze von Physostigminderivaten.
DE69718306D1 (de) Piperidinylpyrimidine derivate
HUP9802290A2 (hu) Pirrolszármazékok és az azokat tartalmazó gyógyászati kompozíciók
DE59915244D1 (de) Kosmetische oder pharmazeutische Zubereitungen enthaltend 1,3,5-Triazinderivate und Zinkoxid
ATE84303T1 (de) Cysteinderivate.
DK363284D0 (da) Endo-8,8-dialkyl-8-azoniabicyclo/3.2.1/octan-6,7-exo-epoxy-3-alkylcarboxylatsalte, fremgangsmaade til fremstilling heraf og terapeutiske praeparater indeholdende disse
DE3861545D1 (de) Aminoverbindungen und diese enthaltende fungizide.
DK656889A (da) Azabicykliske derivater
DE2963724D1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
MD122C2 (ro) Procedeu de obţinere a derivaţilor oxadiazolilalchilpurinei sau a sărurilor ei acide aditive farmacologic acceptabile

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee